# OnCo record paper-paradigm-jama-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-paradigm-jama-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-paradigm-jama-2023" ;
  schema:name "Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial"@en ;
  schema:description "Published report from the PARADIGM trial registered as NCT02394795, in JAMA (2023), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-paradigm-jama-2023/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1001/jama.2023.4428>, <https://pubmed.ncbi.nlm.nih.gov/37071094/>, <https://europepmc.org/article/MED/37071094>, <https://clinicaltrials.gov/study/NCT02394795> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1001/jama.2023.4428> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Watanabe J, Muro K, Shitara K, et al." ;
  onco:trials <https://onco.cc/trials/paradigm/> ;
  onco:journals <https://onco.cc/journals/jama/> .